This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
Subscribe To Our Newsletter & Stay Updated
